The National Oncologic PET Registry (NOPR) is a collaboration of the American College of Radiology Imaging Network (ACRIN), the American College of Radiology (ACR), and the World Molecular Imaging Society (WMIS), to ensure access to Medicare reimbursement for certain types of positron emission tomography (PET) scans.
The National Oncologic PET Registry (NOPR) was developed in response to the Centers for Medicare and Medicaid Services (CMS) proposal to expand coverage for positron emission tomography (PET) with F-18 fluorodeoxyglucose (FDG) to include cancers and indications not presently eligible for Medicare reimbursement. The CMS proposal indicated that Medicare reimbursement for these cancers could be obtained under the CMS coverage with evidence development program, if the patient’s referring physician and the PET provider submitted data to a clinical registry to assess the impact of PET on cancer patient management. The NOPR implemented this registry for CMS.
The NOPR received input from, and is endorsed by, the ACR, the American Society for Clinical Oncology (ASCO), and the Society for Nuclear Medicine and Molecular Imaging (SNMMI).
To find out more about NOPR, visit: http://www.cancerpetregistry.org
Current Running Registry
NOPR (18F NaF) PET 2010 – in progress
February 26, 2010
Centers for Medicare and Medicaid Services (CMS) announced coverage for sodium fluoride F 18 (18F NaF) PET imaging under Coverage with Evidence Development (CED) to: “assist initial antitumor treatment planning or to guide subsequent treatment strategy by the identification, location and quantification of bone metastases in beneficiaries in whom bone metastases are strongly suspected based on clinical symptoms or the results of other diagnostic studies.”
February 7, 2011
The National Oncologic PET Registry (NOPR) began enrolling patients for 18F NaF Bone PET studies.
To find out more or access forms, go to: http://www.cancerpetregistry.org/
NOPR Phase 1: 2006 – 2009
CMS announced a new coverage mechanism for otherwise noncovered cancers and indications with coverage-with-evidence-development policy.
May 8, 2006
NOPR began collecting data on FDG PET performed for cancer indications in Medicare beneficiaries under coverage-with-evidence-development.
Coverage for PET performed for initial treatment strategy of most solid tumors (other than prostate) was expanded by CMS. However, CMS only approved additional subsequent treatment strategy coverage for ovarian, cervical and myeloma. A long list of infrequent cancers continued to be covered by CMS for subsequent treatment strategy under CED program. This started phase 2 in April 2009. Read full press release>>
NOPR Phase 2: 2009 – June 2013
April 6, 2009
A long list of infrequent cancers continued to be covered by CMS for subsequent treatment strategy under CED program.
June 11, 2013
The Centers for Medicare & Medicaid Services (CMS) ended the requirement for coverage with evidence development (CED) under §1862(a
(1)(E) of the Social Security Act (the “Act’) for 18F fluorodeoxyglucose positron emission tomography (FDG PET) for oncologic indications which are contained in section 220.6.17 of the Medicare National Coverage Determinations Manual. This removes the requirement for prospective data collection by the National Oncologic PET Registry (NOPR) for those cancers or cancer types that had been covered under CED. Read “Decision Memo for Positron Emission Tomography (FDG) for Solid Tumors (CAG-00181R4)”>>